Invitae vs Myriad Genetics (2026)
Invitae and Myriad Genetics both run germline genetic testing in their own laboratories and return results to ordering clinicians inside Epic. The difference that decides between them is where each applies machine learning and how much a patient can know about cost up front. Invitae, owned by Labcorp since 2024, tests across oncology, women's health, pediatrics and rare disease, cardiology and neurology, and genetic counseling comes at no added cost. Its Evidence Modeling platform trains gene specific models on curated evidence, keeps only those that pass accuracy thresholds and hands calibrated predictions to the laboratory's scientists as one line of evidence when they classify a variant. More than five million patients have been tested, and more than 400 customer record integrations are live. Myriad Genetics sells the MyRisk hereditary cancer panel, GeneSight, Prequel, Foresight and tumor and residual disease tests. RiskScore, offered with MyRisk, combines a polygenic risk model with the Tyrer-Cuzick model to estimate a woman's lifetime breast cancer risk, weights its variants by genetic ancestry and reports results by ancestry group. Patients see assistance tiers from $0 to $249, and Myriad holds HITRUST r2 certification. A practice ordering across many specialties with counseling built in fits Invitae. A breast cancer risk program that wants a polygenic risk estimate and clear patient cost tiers fits Myriad.
- Testing spans cardiology, neurology, pediatrics and rare disease as well as cancer.
- Patients should receive genetic counseling with the result at no added cost.
- Variant classification should draw on gene specific machine learning evidence.
- The health system already orders Labcorp tests and wants one laboratory relationship.
- Women at average or elevated risk need a lifetime breast cancer risk estimate.
- Risk results should be reported across genetic ancestry groups.
- Patients want to see their likely cost tier before testing.
- Security review asks for HITRUST certification.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Invitae and Myriad Genetics are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Invitae | Myriad Genetics |
|---|---|---|
| Primary category | Diagnostics & Genomics | Diagnostics & Genomics |
| Founded | 2010 | 1991 |
| Headquarters | San Francisco, California, United States | Salt Lake City, Utah, United States |
| Website | invitae.com | myriad.com |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Invitae is a genetic testing brand owned by Labcorp, which acquired the business in 2024 after Invitae's bankruptcy. It keeps its own site and test menu and now presents itself as Invitae and Labcorp together, with some billing handled by Labcorp Genetics. It sells germline testing across oncology, women's health, pediatrics and rare disease, cardiology and neurology, ordered by clinicians and returned with genetic counseling at no additional cost, and reports more than five million patients tested.
Source: AI Health Index, October 2026
Myriad Genetics is a genetic testing company in Salt Lake City, Utah, listed on NASDAQ as MYGN, that runs its tests in its own accredited laboratories. Most of what it sells is laboratory testing: the MyRisk hereditary cancer panel, GeneSight pharmacogenomic testing for mental health medications, Prequel prenatal screening, the Foresight carrier screen, Precise Tumor profiling, Precise MRD monitoring and the MyChoice CDx companion diagnostic.
Source: AI Health Index, October 2026
Questions buyers ask
Is Invitae or Myriad Genetics better for hereditary cancer testing?
Myriad's MyRisk panel comes with RiskScore, a polygenic breast cancer risk estimate weighted by ancestry, and patient cost tiers set out in advance. Invitae tests across a wider range of specialties with genetic counseling included and uses machine learning models as evidence when its scientists classify variants. Both order and result through Epic. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 17, 2026. No vendor pays for placement.
How much do Invitae and MyRisk testing cost patients?
Myriad places patients in financial assistance tiers of $0, $100 or $249 by household income and size, and most eligible MyRisk patients pay nothing after insurance or assistance. Invitae includes genetic counseling at no added cost, and some of its bills now come from Labcorp Genetics. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 17, 2026. No vendor pays for placement.
How do Invitae and Myriad Genetics use machine learning?
Invitae's Evidence Modeling platform trains gene specific models on curated evidence to support variant classification by its scientists. Myriad's RiskScore estimates lifetime breast cancer risk from a polygenic risk model and the Tyrer-Cuzick model, and Prolaris + AI adds a licensed digital pathology model for prostate cancer surveillance. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 17, 2026. No vendor pays for placement.
What is Myriad's RiskScore?
RiskScore, offered with the MyRisk panel, combines a polygenic risk model with the Tyrer-Cuzick model to estimate a woman's lifetime breast cancer risk. It weights its variants by genetic ancestry and reports results by ancestry group. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 17, 2026. No vendor pays for placement.
Who owns Invitae?
Labcorp has owned Invitae since 2024, when it acquired the business after Invitae's bankruptcy. Invitae keeps its own site and test menu, now presented as Invitae and Labcorp together. Myriad Genetics is independent and listed on NASDAQ as MYGN. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 17, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Diagnostics & Genomics page.
Invitae, based in San Francisco, has been owned by Labcorp since 2024, after Invitae's bankruptcy, and some bills now come from Labcorp Genetics. Myriad Genetics is listed on NASDAQ as MYGN and based in Salt Lake City. Neither gives a hosting location for sequence data, and both offer their tests as laboratory developed tests without FDA clearance for the machine learning inside them.